All Stories

  1. Role of Hyaluronic Acid and Chondroitin Sulphate in Protecting Urinary Epithelium in Patients Operated for Differentiated Thyroid Cancer Undergoing Ablation Therapy with Iodine-131
  2. Morpho-Functional and Biochemical Characterization of Adrenal Masses in a Heterogeneous Cancer Population
  3. Validation of a Ready-to-Use Lyophilized Kit for Labeling IL2 with 68Ga: A New Avenue for Imaging Activated T-lymphocytes in Tumor Microenvironment
  4. [68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects
  5. EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0
  6. Intra and Inter-Rater Variability in the Interpretation of White Blood Cell Scintigraphy of Hip and Knee Prostheses
  7. Radiolabelled FGF-2 for Imaging Activated Fibroblasts in the Tumor Micro-Environment
  8. Peritoneal Carcinomatosis of Malignant Gynecological Origin: A Systematic Review of Imaging Assessment
  9. SARS-CoV-2 Affects Thyroid and Adrenal Glands: An 18F-FDG PET/CT Study
  10. Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates
  11. Imaging of Vascular Graft/Endograft Infection with Radiolabeled White Blood Cell Scan and [18F]FDG PET/CT
  12. Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use
  13. Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma
  14. A Systematic Review on Combined [18F]FDG and 68Ga-SSA PET/CT in Pulmonary Carcinoid
  15. Radioimmune Imaging of α4β7 Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease
  16. [18F]FDG Uptake in Non-Infected Endovascular Grafts: A Retrospective Study
  17. Evidence-based medicine: reviews and meta-analysis
  18. Present status and future trends in molecular imaging of lymphocytes
  19. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent
  20. Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update
  21. PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
  22. [18F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab
  23. Methods for Radiolabelling Nanoparticles: PET Use (Part 2)
  24. Methods for Radiolabelling Nanoparticles: SPECT Use (Part 1)
  25. Sjögren Syndrome: New Insights in the Pathogenesis and Role of Nuclear Medicine
  26. Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren’s Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications
  27. Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study
  28. Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series
  29. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation
  30. Basic statistics for nuclear medicine and radiology
  31. Gamma camera imaging of autoimmune diseases
  32. Gamma camera imaging of inflammatory bowel diseases
  33. Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR)
  34. Synthesis and Biodistribution of 99mTc-Labeled PLGA Nanoparticles by Microfluidic Technique
  35. An easy and practical guide for imaging infection/inflammation by [18F]FDG PET/CT
  36. In Vivo Imaging of Thyroid Cancer with 99mTc-TR1401 and 99mTc-TR1402: A Comparison Study in Dogs
  37. PET and SPECT Imaging of Tumor Micro-Environment: A Systematic Review of the Last 20 Years
  38. Extensive Histopathological Characterization of Inflamed Bowel in the Dextran Sulfate Sodium Mouse Model with Emphasis on Clinically Relevant Biomarkers and Targets for Drug Development
  39. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2
  40. In Vitro and In Vivo Evaluation of 99mTc-Polymyxin B for Specific Targeting of Gram-Bacteria
  41. Molecular Imaging of Autoimmune Diseases
  42. Handling of Doubtful WBC Scintigraphies in Patients with Suspected Prosthetic Joint Infections
  43. Imaging Bacteria with Radiolabelled Probes: Is It Feasible?
  44. Diabetic Foot Infections: The Diagnostic Challenges
  45. Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles
  46. Comparison of White Blood Cell Scintigraphy, FDG PET/CT and MRI in Suspected Diabetic Foot Infection: Results of a Large Retrospective Multicenter Study
  47. Imaging Modalities for the Diagnosis of Vascular Graft Infections: A Consensus Paper amongst Different Specialists
  48. RE: 99m Tc‐HMPAO‐leucocyte scintigraphy and [ 18 F]FDG‐PET/CT in infection
  49. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System
  50. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy
  51. Nuclear Medicine in Infectious Diseases
  52. Nuclear Medicine Imaging of Diabetic Foot Infections
  53. Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review
  54. Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults
  55. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
  56. State of the Art of Natural Killer Cell Imaging: A Systematic Review
  57. Letter to the Editor regarding Falstie-Jensen et al: “Labeled white blood cell/bone marrow single-photon emission computed tomography with computed tomography fails in diagnosing chronic periprosthetic shoulder joint infection”
  58. Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  59. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
  60. Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome
  61. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
  62. 99mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study
  63. Labelling and Clinical Performance of Human Leukocytes Labelled with 99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent
  64. The reconstructed natural history of type 1 diabetes mellitus
  65. Correction to: Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  66. PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review
  67. Comparison of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTc-ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study
  68. Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  69. Consensus document for the diagnosis of peripheral bone infection in adults: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement)
  70. Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells
  71. Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging
  72. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study
  73. Leukocyte Imaging of the Diabetic Foot
  74. Infection and inflammation imaging standardization: the EANM guidelines
  75. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline
  76. Radiolabelled nanoparticles for cancer diagnosis
  77. Recommendations on nuclear and multimodality imaging in IE and CIED infections
  78. Current Status of Molecular Imaging in Infections
  79. Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders
  80. Editorial: Molecular Imaging of Inflammation/Infection: The Future of Disease Management
  81. Molecular Imaging of Inflammatory Arthritis and Related Disorders
  82. New SPECT and PET Radiopharmaceuticals for Imaging Inflammatory Diseases: A Narrative Review
  83. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC
  84. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study
  85. Animal models for the study of inflammatory bowel diseases: a meta-analysis on modalities for imaging inflammatory lesions
  86. Hybrid fusion images in diagnostic and therapeutic procedures
  87. Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria
  88. Hybrid imaging of musculoskeletal infections
  89. In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy
  90. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the Americ...
  91. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET
  92. Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study.
  93. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast
  94. Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis
  95. Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory Diseases
  96. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype
  97. OUP accepted manuscript
  98. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis
  99. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis
  100. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany
  101. Corrigendum
  102. Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review
  103. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: a pilot study
  104. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)
  105. In vivo imaging of microorganisms
  106. Isolation and 111In–Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model
  107. Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors
  108. Comment on: “Diagnosis of Periprosthetic Joint Infection: The Role of Nuclear Medicine May Be Overestimated” by Claudio Diaz-Ledezma, Courtney Lamberton, Paul Lichtstein and Javad Parvizi
  109. 99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis
  110. In Vivo Imaging of Natural Killer Cell Trafficking in Tumors
  111. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
  112. Somatostatin Receptor Scintigraphy-Spect
  113. The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis
  114. Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
  115. Somatostatin Analogues
  116. Detection of Insulitis By Pancreatic Scintigraphy With99mTc-Labelled-IL2 and MRI in Patients With LADA (Action LADA 10)
  117. Imaging Infection and Inflammation
  118. In VivoEvaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis
  119. Imaging in dermal filler diagnostics: MRI how and why
  120. 99mTc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer
  121. Infection and inflammation imaging
  122. Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
  123. Comment on Aksoy et al.: FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection
  124. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery
  125. Reply to comment by Koranda: 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections—the choice of reference tissue for a semiquantitative analysis
  126. Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study
  127. Nuclear Medicine Imaging Modalities: Bone Scintigraphy, PET-CT, SPECT-CT
  128. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
  129. A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections
  130. Diagnostic Imaging of Infections and Inflammatory Diseases
  131. Nuclear Medicine Imaging of Infections: Techniques, Acquisition Protocols and Interpretation Criteria
  132. Nuclear Medicine Imaging of Inflammatory Diseases
  133. Nuclear Medicine Imaging of Tuberculosis and Human Immunodeficiency Virus
  134. High Sensitive Thyroglobulin Assay on Thyroxine Therapy: Can it Avoid Stimulation Test in Low and High Risk Differentiated Thyroid Carcinoma Patients?
  135. Biological Therapies for Rheumatoid Arthritis: Progress to Date
  136. EANM/SNMMI Guideline for 18F-FDG Use in Inflammation and Infection
  137. Leukocyte and bacteria imaging in prosthetic joint infection
  138. About inflammation and infection
  139. The Use of18F-FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases
  140. Nuclear Medicine Imaging of Abdominal Infections and Inflammation
  141. Nuclear Medicine Imaging of Infections and Inflammation of Central Nervous System, Head and Neck Structures
  142. Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications
  143. Imaging of β-Cell Mass and Insulitis in Insulin-Dependent (Type 1) Diabetes Mellitus
  144. 11C-Hydroxytryptophan Uptake and Metabolism in Endocrine and Exocrine Pancreas
  145. The Role of Positron Emission Tomography in Inflammatory Bowel Disease
  146. Differences in the location and activity of intestinal Crohn’s disease lesions between adult and paediatric patients detected with MRI
  147. Added Value of 99mTc-HMPAO-Labeled Leukocyte SPECT/CT in the Characterization and Management of Patients with Infectious Endocarditis
  148. Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation
  149. New frontiers of MRI in Crohn’s disease: motility imaging, diffusion-weighted imaging, perfusion MRI, MR spectroscopy, molecular imaging, and hybrid imaging (PET/MRI)
  150. Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis
  151. N-(4-18F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes
  152. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement?
  153. 99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients
  154. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques
  155. Can Sequential 18F-FDG PET/CT Replace WBC Imaging in the Diabetic Foot?
  156. Time for radiobiology in the nuclear medicine community
  157. In vivo biodistribution of stem cells using molecular nuclear medicine imaging
  158. 99mTc-besilesomab (Scintimun®) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells
  159. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections
  160. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide
  161. Synthesis and Evaluation of 99mTc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression
  162. FDG-PET/CT in infections: the imaging method of choice?
  163. Molecular Imaging of Inflammation/Infection: Nuclear Medicine and Optical Imaging Agents and Methods
  164. Erratum to: Guidelines for the labelling of leucocytes with 99mTc-HMPAO
  165. Erratum to: Guidelines for the labelling of leucocytes with 111In-oxine
  166. Molecular imaging in atherosclerosis
  167. Guidelines for the labelling of leucocytes with 111In-oxine
  168. Guidelines for the labelling of leucocytes with 99mTc-HMPAO
  169. Imaging of cell trafficking in Crohn's disease
  170. Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes
  171. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies
  172. Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes
  173. Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes
  174. Peptide receptor therapies in neuroendocrine tumors
  175. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients
  176. Long-term survival of endodontically treated, maxillary anterior teeth restored with either tapered or parallel-sided glass-fiber posts and full-ceramic crown coverage
  177. The Contribution Of Nuclear Medicine In The Diagnosis Of Bone Metastases
  178. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor  
  179. Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3
  180. Receptor Binding Ligands to Image Infection
  181. Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
  182. Decontamination of Root Canals with the Gallium-Aluminum-Arsenide Laser: Anin VitroStudy
  183. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study
  184. Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck
  185. Studying the Metabolic Activity of Red Bone Marrow by Means of FDG-PET: The Need for a Standardization
  186. Can we produce an image of bacteria with radiopharmaceuticals?
  187. Prognostic Value of CD25 Expression on Lymphocytes and Tumor Cells in Squamous-Cell Carcinoma of the Head and Neck
  188. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy
  189. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma
  190. Radiopharmaceuticals for imaging chronic lymphocytic inflammation
  191. Diagnosis of Vascular Prosthesis Infection: PET or SPECT?
  192. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma
  193. ANNEXIN V DETECTION OF LIPOPOLYSACCHARIDE-INDUCED CARDIAC APOPTOSIS
  194. Yeasts and filamentous fungi in bottled mineral water and tap water from municipal supplies
  195. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis
  196. Nuclear medicine imaging of bone infections
  197. Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis
  198. Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes
  199. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques
  200. Inflammatory bowel diseases: clinical update of practical guidelines
  201. Nuclear medicine imaging of inflammatory/infective disorders of the abdomen
  202. Small animal imaging by single photon emission using pinhole and coded aperture collimation
  203. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with 99mTc‐infliximab
  204. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy
  205. Biological evaluation of a polyvinyl siloxane impression material
  206. CT60 Single Nucleotide Polymorphisms of the Cytotoxic T-Lymphocyte–Associated Antigen-4 Gene Region is Associated with Graves' Disease in an Italian Population
  207. High Plasma Levels of Human Chromogranin a and Adrenomedullin in Patients with Pheochromocytoma
  208. The 17th International IRIST Congress Proceedings
  209. Scientific production and impact of nuclear medicine in Europe: how do we publish?
  210. 99mTc-EDDA/HYNIC-TOC in the Management of Medullary Thyroid Carcinoma
  211. Radiolabeled Annexin-V for Monitoring Treatment Response in Oncology
  212. Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003
  213. Radioiodinated Recombinant Human TSH: A Novel Radiopharmaceutical for Thyroid Cancer Metastases Detection
  214. The Proceedings of the 16th IRIST (International Research Group on Immunoscintigraphy and Therapy) Congress
  215. FDG-PET in infectious and inflammatory disease
  216. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract
  217. Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer
  218. False-Negative Tc-99m MIBI Scintigraphy in Histopathologically Proved Recurrent High-Grade Oligodendroglioma
  219. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases
  220. 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease
  221. Novel PET and SPECT radioligands for visualization of diseased regulatory pathways in breast carcinoma
  222. Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice
  223. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine
  224. Inflammatory Bowel Diseases: The Use of Radiolabelled Cytokines for In Vivo Evaluation of Inflammatory Activity
  225. Nuclear Medicine in the Management of Inflammatory and Infectious Diseases
  226. EDITORIAL
  227. Radiolabelled cytokines for imaging chronic inflammation
  228. Discordant Findings Between Tc-99m HMPAO Mixed Leukocytes and Tc-99m–Labeled Monoclonal Antibody Fragments (via LeukoScan) in a Patient with Pulmonary Aspergillosis
  229. Peptide Receptor Imaging
  230. Nuclear Medicine Imaging For Prediction or Early Assessment of Response to Chemotherapy in Patients Suffering From Breast Carcinoma
  231. Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging
  232. Biological Imaging for the Diagnosis of Inflammatory Conditions
  233. Assessment of Cancer-Associated Biomarkers by Positron Emission Tomography: Advances and Challenges
  234. Peptide radiopharmaceuticals for diagnosis and therapy
  235. Erratum to: Peptide radiopharmaceuticals for diagnosis and therapy
  236. Editorial
  237. THE DEVELOPING ROLE OF CYTOKINES FOR IMAGING INFLAMMATION AND INFECTION
  238. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet
  239. Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor
  240. CTLA-4 and HLA gene susceptibility to thyroidassociated orbitopathy
  241. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma
  242. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI)
  243. Characterization of a New Form of Inherited Hypercholesterolemia
  244. In vivo imaging of insulitis in autoimmune diabetes
  245. Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes
  246. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse
  247. A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime
  248. CD95 ligand expression on alpha cells: protection or killing?
  249. Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes
  250. CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice
  251. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele
  252. 4.P.288 The metabolic basis of a new form of recessive hypercholesterolemia: The “FH-like” hypercholesterolemia
  253. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)
  254. The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the In vivo detection of mononuclear cell infiltrates in immune-mediated diseases
  255. Metformin Does Not Alter Diabetes Incidence in the NOD Mouse
  256. Radiopharmaceuticals for the study of 4 inflammatory processes
  257. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes
  258. Standardizing Experiments with NOD Mice
  259. Effect of metformin on liver insulin metabolism and regional blood flow
  260. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study)
  261. Usefulness of scintigraphy using 99mTc-EMPAO labelled granulocytes (PMN) as early indicator of postoperative asymptomatic recurrence in Crohn's disease (CD)
  262. New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2
  263. Nicotinamide vs Steroids in Recent-Onset Diabetes: Impact on 3-Cell Function
  264. Histological study of pancreatic beta-cell loss in relation to the insulitis process in the non-obese diabetic mouse
  265. Randomized Trial Comparing Nicotinamide and Nicotinamide Plus Cyclosporin in Recent Onset Insulin-dependent Diabetes (IMDIAB 1)
  266. A simple method for the evaluation of receptor binding capacity of modified cytokines
  267. The effect of a heparin analogue, ITF-5005, on diabetes incidence and insulitis in the non-obese diabetic mouse
  268. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse
  269. NOD mouse colonies around the world- recent facts and figures
  270. What future for therapeutic prevention of Type I (insulin-dependent) diabetes mellitus?
  271. A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies
  272. Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse
  273. Clinical remission in patients with IDDM and family history of NIDDM
  274. Raised temperature reduces the incidence of diabetes in the NOD mouse
  275. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type 1 (insulin-dependent) diabetes mellitus
  276. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice
  277. In vivo kinetics of 1231-labelled insulin
  278. Imaging of leukocytic infiltration in human cerebral infarcts.
  279. Labelling of lymphocytes with indium 111 oxine: Effect on cell surface phenotype and antibody-dependent cellular cytotoxicity